Read the study published in Clinical Gastroenterology and Hepatology, co-authored by Dr. Jennifer Telford, medical director of the BC Cancer Colon Screening Program, analyzing data from the BC Colon Screening Program.
Congratulations to Dr. Marco Marra on receiving the 2025 Lifetime Contribution Prize from the Canadian Cancer Society, in recognition of his transformative impact on cancer genomics research, precision medicine and scientific mentorship.
Read the Canadian Cancer Trials Group story on the launch of the ALC.10 (MM1OA-EA02) study.
Congratulations to the BC Cancer – Kelowna IND240 Clinical Trials Team on receiving the IND Team Award from the Canadian Cancer Trials Group (CCTG), presented at the CCTG Spring Meeting.
The award recognizes non-MD trial team members for their outstanding contributions and dedication to the success of clinical trials within the IND Program.
A groundbreaking new blood test developed by BC Cancer is changing how families identify and manage inherited cancer risk, eliminating unnecessary testing on one side of a family while bringing life-saving clarity to the other.
BC Cancer scientists have developed a world-first technology, Parent-of-Origin-Aware Genomic Analysis (POAga) which can determine, with 98% accuracy, whether a cancer-causing gene mutation was inherited from a patient's mother or father – using only a single blood sample.
A new Canadian Cancer Trials Group (CCTG) survey study, SC32S, has opened across Canada to collect sociodemographic data from cancer clinical trial participants and assess whether asking questions about this information feels appropriate to patients. The patient survey will ask CCTG trial participants about different parts of everyday life that can affect patient health and experience with cancer care.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.